title: Are ALK rearrangement variants promising predictive biomarker of ALK tyrosine kinase inhibitors efficacy?
authors.affiliation: Thoracic Oncology Unit, Respiratory Medicine Department, CHU Grenoble Alpes, Grenoble.|UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences.|Grenoble Alpes University, Grenoble.
authors.forename: M
authors.initials: M
authors.lastname: Duruisseaux
authors.affiliation: UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences.|Grenoble Alpes University, Grenoble.|Cancer Molecular Genetics Platform, Biology and Pathology Institute, CHU Grenoble Alpes, Grenoble.
authors.forename: A
authors.initials: A
authors.lastname: Mc Leer-Florin
authors.affiliation: Thoracic Oncology Unit, Respiratory Medicine Department, CHU Grenoble Alpes, Grenoble.|UGA/INSERM U1209/CNRS 5309, Institute for Advanced Biosciences.|Grenoble Alpes University, Grenoble.
authors.forename: D
authors.initials: D
authors.lastname: Moro-Sibilot
authors.affiliation: Respiratory Medicine Department, Tenon Hospital, AP-HP, GH HUEP, Paris.|Sorbonne University, UPMC Université de Paris 06, GRC n°04, Theranoscan, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Cadranel
mesh_terms: D015415:Biomarkers; D002289:Carcinoma, Non-Small-Cell Lung; D015321:Gene Rearrangement / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms; D047428:Protein Kinase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D015415:Biomarkers; D047428:Protein Kinase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases